Trials / Completed
CompletedNCT06802796
Plasma NGAL in APN Patients
Plasma NGAL as a Predictor to Acute Pyelonephritis : Case -Control Cohort Study .
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (actual)
- Sponsor
- Kafrelsheikh University · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
In recent years, novel biomarkers of renal dysfunction have attracted attention for the diagnosis of UTIs. NGAL is a 25 kDa protein that belongs to the lipocalin. It acts as a transporter for small hydrophobic molecules and is involved in many physiological processes, such as modulating inflammation, innate immune response, and maintaining metabolic homeostasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Plasma NGAL test | Human neutrophil gelatinase-associated lipocalin ELISA Kit from BT LAB® Bioassay technology laboratory was used for the estimation of serum NGAL. Procedure was done according to the manufacturer's instructions. |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2024-06-01
- Completion
- 2024-06-01
- First posted
- 2025-01-31
- Last updated
- 2025-01-31
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06802796. Inclusion in this directory is not an endorsement.